Skip to content

Application of recombinant human superoxide dismutase to prevnet and treat radiation induced vaginal mucosal injury for cervical cancer treated with concurrent chemoradiotherapy

Application of recombinant human superoxide dismutase to prevnet and treat radiation induced vaginal mucosal injury for cervical cancer treated with concurrent chemoradiotherapy: a multicenter, randomized, open-label, prospective trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096277
Enrollment
Unknown
Registered
2025-01-21
Start date
2025-01-21
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

experimental group:vaginal douching with recombinant human superoxide dismutase
control group:vaginal douching with normal saline

Sponsors

Peking University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1: Patients are fully voluntary and self-directed, signing an informed consent for the study within 30 days prior to enrollment 2: Age >= 18 and =1.5*10^9/L, HGB>=80g/L, PLT>=100*10^9/L, creatinine < 1.5mg/dl (133umol/L), AST and ALT <=2ULN.

Exclusion criteria

Exclusion criteria: 1: Prior history of allergy to recombinant human superoxide dismutase 2: Patients with skin and mucous membrane infections, obvious uterine pus or pelvic inflammatory disease 3: Patients who have undergone surgery (including pelvic or retroperitoneal lymph node dissection, excluding tumor biopsy), radiation therapy or chemotherapy for cervical cancer 4: Those who are not expected to be able to undergo brachytherapy, or whose brachytherapy requires the use of an aneurysm curettage, separate placement of uterine tubes and foramen ovale tubes, or a template program 5: History of other malignant tumors 6: Pregnant or lactating women 7: With active infection, fever 8: Other serious medical conditions that may significantly affect compliance with clinical trials, such as unstable heart disease requiring treatment, kidney disease, chronic hepatitis, poorly controlled diabetes, and psychiatric disorders

Design outcomes

Primary

MeasureTime frame
Incidence of acute and chronic vaginal injuries in patients within 2 years from the start to the end of radiation therapy;

Secondary

MeasureTime frame
>=Incidence of grade >=2 acute and chronic vaginal injuries in patients within 2 years from the start to the end of radiation therapy;Vaginal flora diversity;2-year OS, 2-year PFS;Quality of life before, during and after radiotherapy;

Countries

China

Contacts

Public ContactXiaofan Li

Peking University Cancer Hospital

lxflp@163.com+86 10 8819 6991

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026